Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
Authors:
- Alexander SchmitzASAlexander Schmitz
- Rasmus Froberg BrøndumRBRasmus Froberg Brøndum
- Hans Erik JohnsenHJHans Erik Johnsen
- Ulf-Henrik MellqvistUMUlf-Henrik Mellqvist
- Anders WaageAWAnders Waage
- Peter GimsingPGPeter Gimsing
- Davine Hofste Op BruininkDBDavine Hofste Op Bruinink
- Bronno van der HoltBHBronno van der Holt
- Markus HanssonMHMarkus Hansson
- Ulf Christian FrølundUFUlf Christian Frølund
Open Access
- 5 February 2022
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
Abstract
Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments. Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitdudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression. Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with ≥3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease and clinical progression by 5.5 months and 12.6 months (mean values), respectively. Mean malignant plasma cells doubling time for the six patients was 1.8 months (95% CI, 1.4–2.3 months). Minimal malignant plasma cells detection limit was 4 × 10–5. Conclusions: Flow-MRD is a sensitive method for longitudinal monitoring of minimal residual disease dynamics in multiple myeloma patients in complete response. Increasing minimal residual disease levels precedes biochemically assessed changes and is an early indicator of subsequent clinical progression. Trial registration: NCT01208766Keywords
This publication has 56 references indexed in Scilit:
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patientsHaematologica, 2009
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Early response to therapy and survival in multiple myelomaBritish Journal of Haematology, 2004